Clemondo Group (CLEM) Q1 2025 earnings summary

Executive summary

• Achieved 12% year-over-year revenue growth in Q1 2025, reaching 75.1 MSEK, with profitability improvements across all market areas.

• EBITDA increased to 7.9 MSEK (10.3% margin), EBIT to 4.3 MSEK, and net income to 3.1 MSEK, all up significantly from Q1 2024.

• Strategic focus shifted to Medical Care, which became a key growth driver after a major contract win and product reclassification.

• CEO transition initiated after six years of leadership, with recruitment of a new CEO underway.

Financial highlights

• Revenue: 75.1 MSEK, up from 67.3 MSEK in Q1 2024 (+12%).

• EBITDA: 7.9 MSEK (10.3% margin) vs. 5.7 MSEK (8.2%) last year.

• EBIT: 4.3 MSEK (5.6% margin) vs. 1.9 MSEK (2.8%).

• Net income: 3.1 MSEK vs. 1.1 MSEK; EPS: 0.23 SEK vs. 0.08 SEK.

• Cash flow from operations improved to 5.7 MSEK from -0.2 MSEK.

Outlook and guidance

• Medical Care segment positioned as primary growth engine, supported by new contracts and product upgrades.

• Company maintains focus on sustainable solutions and expects continued growth despite external uncertainties.